Chuong Dinh Hoang, M.D.
Dr. Hoang is a surgeon-scientist sub-specialized in thoracic surgical oncology. His research section (RNA Biology and Applied Therapeutics) is concerned with the comprehensive identification, understanding of mechanisms, innovating delivery methods, and preclinical development of promising candidate therapeutic microRNAs against thoracic cancers. This translational research pipeline also serves to generate hypothesis-driven projects aimed at biomarker discovery for purposes of diagnosis, prognosis, and response evaluation. Extensive multi-disciplinary collaborations ranging from computational systems biology to materials science and chemistry have been established to achieve these broad goals. His lab uses malignant pleural mesothelioma as a model to integrate and validate these research endeavors. Other thoracic cancers such as thymic epithelial tumors and non-small cell lung carcinomas are also of interest with ongoing research project development. His clinical expertise includes all the major aspects of thoracic surgery including procedures for lung cancer, other primary lung tumors, mesothelioma, thymic malignancies, esophageal cancer, pulmonary metastases, Pancoast tumors, and tracheal cancers. He utilizes the latest techniques in endoscopic and minimally-invasive (VATS and robotic) thoracic surgery.
1) malignant mesothelioma, 2) thymic epithelial tumors, 3) non-small cell lung cancer,
4) esophageal cancer, 5) pulmonary metastatic cancers, 6) minimally invasive thoracic surgery, 7) thoracic endoscopy, 8) microRNA
My research interests are in developing novel biomarkers and therapeutic strategies in thoracic cancers (malignant mesothelioma, thymic epithelial tumors, non-small cell lung carcinoma, etc.) by systematically identifying and exploiting disease-specific microRNA delivered in vivo via novel clinical delivery system(s).
Selected Recent Publications
- Molecular Therapy. 27(9): 1665-1680, 2019. [ Journal Article ]
Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling.Translational Oncology. 12(6): 859-870, 2019. [ Journal Article ]
- Chest. 144(5): 1632-43, 2013. [ Journal Article ]
- Translational Lung Cancer Research. Jun;6(3): 248-258, 2017. [ Journal Article ]
Liquid chromatography/mass spectrometry methods for measuring dipeptide abundance in non-small-cell lung cancer.Rapid Commun Mass Spectrom. 27(18): 2091-8, 2013. [ Journal Article ]
Dr. Hoang received his medical degree from the University of Minnesota Medical School, where he stayed to complete clinical training in general surgery. During his surgical residency his research work was supported by the Ruth L. Kirschstein National Research Service Award and a Training Program Grant in the Division of Hematology-Oncology. Afterwards, Dr. Hoang completed his cardiothoracic residency at the University of Pennsylvania, with an emphasis on thoracic surgery. Since 2008, he then served on faculty at Stanford University School of Medicine as an Assistant Professor. He was the Medical (co-)Director of the Stanford Cancer Center Tissue Bank. Dr. Hoang also established an independent thoracic oncology laboratory there investigating the metabolic derangements in lung cancer and microRNA interactions in mesothelioma.
|Nathanael D. Pruett, Ph.D.||Research Biologist|
|Anand Singh, Ph.D.||Postdoctoral Fellow (Visiting)|
|Colleen D. Bond A.C.N.P.||Nurse Practitioner|
|Cheryl Warga C.R.N.P.||Nurse Practitioner|
|Tricia Kunst R.N.||Research Nurse|
|James P. Madigan, Ph.D.||Staff Scientist|
|Roxanne Merkel R.N.||Research Nurse|
|Jan Pappas||Program Support Specialist|
|Ingrid Vasquez||Patient Care Coordinator (Contr.)|